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ABSTRACT 
In this research we propose a nanoplatform for anticancer therapy that is based on the 
combination of three components: 1) an antibiotic to target selectively the mitochondria 
of cancer cells, inhibiting their functions; 2) mineral nanoparticles (NPs) able to 
encapsulate the antibiotic and to enter into the cells across the cell membrane; and 3) a 
biocoating to protect the antibiotic during and/or after its regulated release, increasing 
its therapeutic efficacy. Chloramphenicol (CAM), a prototypical wide-spectrum 
antibiotic, has been used to induce mitochondrial-dysfunctions in cancer cells. Different 
in situ synthetic strategies have been tested to load such antibiotic into both crystalline 
hydroxyapatite (cHAp) and amorphous calcium phosphate (ACP) NPs. cHAp NPs 
showed higher loading capacity, in terms of encapsulation and superficial adsorption of 
CAM, and slower antibiotic release than ACP NPs. On the other hand, the protecting 
role played by biocoatings based on pyrophosphate and, especially, triphosphate was 
greater than biophosphonates, the anticancer therapeutic efficacy of CAM being 
maximized by the formers. In vitro studies using healthy and cancer cell lines have 
demonstrated that in situ CAM-loaded cHAp NPs coated with triphosphate selectively 
kill a great population of cancer cells, evidencing the potential of this nanoplatform in 
cancer treatment. 
 
Keywords: Antibiotic; Biocoating; Calcium phosphate; Cancer cells; Chloramphenicol; 
Polyphosphate 
 
  
3 
 
INTRODUCTION 
Bone is a calcified tissue composed of 50 to 70% mineral, 20 to 40% organic matrix, 
5 to 10% water, and <3% lipids. The mineral content of bone is mostly hydroxyapatite 
(HAp) [Ca10(PO4)6(OH)2], with small amounts of carbonate, magnesium, and acid 
phosphate. Compared to geologic HAp crystals, bone HAp crystals are very small, 
measuring only approximately 200 nm in their longest dimension. The solubility of 
these small crystals is higher than that of geologic HAp crystals, allowing them to 
support metabolism. Currently, synthetic HAp is one of the most widely used 
biomaterials for reconstruction of the skeleton due to the lack of local or systemic 
toxicity in combination with its osteoconductive properties.
1-6
 
On the other hand, antibiotics that target bacterial ribosome have a common 
mechanism of action: they are protein synthesis inhibitors.
7
 The main target for such 
group of antibiotics is the peptidyl transferase center,
8
 which forms peptide bonds 
between adjacent amino acids using tRNA during the protein biosynthesis.
9
 
Accordingly, the therapeutic success of ribosomal antibiotics killing bacteria is based on 
the discrimination between prokaryotic and eukaryotic ribosome structures, which 
exhibit differences in size, sequence, structure, and the ratio of protein to RNA.
10,11
 
Chloramphenicol (CAM) is a prototypical wide-spectrum antibiotic that obstructs 
protein synthesis and blocks essential ribosomal functions.
12-14
 CAM consists of a p-
nitrophenyl ring attached to a dichloroacetyl tail via a 2-amino-1,3-propanediol moiety 
(Scheme 1). Thus, CAM incorporates itself to the C-terminus of a growing peptide 
chain, causing the premature release of the incomplete peptide. 
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On the other hand, a growing body of experimental evidences has shown that some 
antibiotics may inhibit mitochondrial functions of eukaryotic cells, causing changes at 
both molecular and physiological levels that affect the life and death of cells.
15,16
 This 
has been attributed to the fact that mitochondrial ribosomes resemble many features of 
bacterial ribosomes. The metabolism of cancer cells, especially of cancer stem cells, is 
fundamentally regulated by an abundance of mitochondria compared to normal cells, 
including normal stem cells.
17
 Thus, the low energy efficiency of the mostly anaerobic 
metabolism of cancer cells is compensated with more mitochondria than normal cells, 
which exhibit an aerobic metabolism. Accordingly, clinical oncologists have recently 
proposed the use of antibiotics as a part of anticancer therapy and target cancer 
metabolisms.
17-20 
Within this context, in a recent study Lisante et al.
17
 proved that CAM 
inhibits the formation of tumor stem cells, which are the responsible of metastasis by 
giving growth to new tumors.
21
 The anticancer activity of CAM and other antibiotics 
reached great repercussion for its implications in clinical oncology.
18
 
 
Synthetic HAp has an enormous capacity not only to encapsulate biomolecules (e.g. 
nucleic acids and proteins
22,23
) but also to adsorb a variety bio-organic and inorganic 
chemical species (e.g. DNA,
24
 amino acids,
25,26
 phosphate- and biophosphonate-
derivatives
27
). HAp-based platforms have been used for bone regeneration through 
adsorbing inorganic polyphosphates from the metabolism onto the mineral,
28-31
 for the 
fight against different bone diseases (e.g. osteoporosis, Paget disease of bone and 
malignancies metastatic to bone) through the delivery of biophosphonates as 
pharmacological agents,
32,33
 and for gene delivery by transfecting cells, as HAp is able 
to adsorb, transport and deliver nucleic acids inside the cell nucleus.
24,34,35
  
The current study focuses on antitumoral nanoplatforms that combine the ability of 
CAM to inhibit the mitochondrial functions and the capacity of HAp to encapsulate 
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biomolecules and enter into cells. For this purpose, CAM-loaded mineral nanoparticles 
(NPs) covered with an inorganic biocoating have been prepared and characterized. After 
this, we have demonstrated that such biocoated CAM-containing systems satisfy the 
most important criteria required by therapeutic nanoplatforms (e.g. the loaded antibiotic 
preserves the bioactive conformation and its release is regulated by the physical 
properties of both the NPs and the biocoating). Finally, different inhibitory effects of the 
proposed antitumoral nanoplatforms have been examined on both normal cells 
(HUVEC endothelial line and COS-1 fibroblast line) and cancer cells (MCF-7 breast 
cancer line and MIA PaCa-2 pancreas cancer line). The selectivity of biocoated HAp 
NPs loaded with CAM on killing cancer cells proves their potential application in 
cancer treatment. 
 
RESULTS AND DISCUSSION 
Chloramphenicol-loaded hydroxyapatite: Preparation and characterization 
Because of their different characteristics and properties, both crystalline HAp 
(cHAp) and amorphous calcium phosphate (ACP) NPs have been considered for this 
study. The experimental conditions used to prepare unloaded cHAp and ACP NPs
24,27
 
were adapted for the in situ loading of CAM. In both cases a 0.5 M (NH4)2HPO4 
aqueous solution was added drop-wise and under agitation to a 0.5 M Ca(NO3)2 ethanol 
solution, reagents being adjusted to get a Ca/P ratio of 1.67. The resultant suspension 
was aged for 24 h at 37 ºC to produce ACP, whereas cHAp was obtained by applying 
hydrothermal conditions during 24 h. Details of the experimental conditions and 
procedures are provided in the Supporting Information. 
CAM-loaded NPs were prepared using four different in situ loading strategies: 2 
minerals (cHAp or ACP)  2 loading paths of the antibiotic into the corresponding 
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(NH4)2HPO4 or Ca(NO3)2 feeding solution (Pho- or Ca-path, respectively) = 4 
strategies. The nomenclature used for the resulting NPs is indicated in Figure 1a.  
The loading efficiency (LEff), which is expected to be sensitive to the path because 
of the different strength of CAM···
3
4PO  and CAM···Ca
2+
 interactions, was evaluated 
by UV-vis spectroscopy. The in situ loading strategies used in this work cause both the 
entrapment of CAM inside the mineral matrix (i.e. encapsulation or mineralization) and 
the adsorption of CAM on the surface mineral NPs. In order to distinguish between such 
two situations, the LEff was determined considering: (i) the CAM extracted from the 
mineral surface by washing with a phosphate buffered saline (PBS) solution 
supplemented with 70% v/v ethanol (PBS-EtOH) during several hours; and (ii) the 
CAM encapsulated into mineral NPs that, after washing as in (i), were dissolved in a 
100 mM HCl : 50 mM NaCl mixture. The UV-vis spectra of samples coming from (i) 
and (ii) showed the absorption band of the p-nitrophenyl chromophore (Scheme 1) at 
around 278 nm.
36
 The intensity of the peaks increased gradually with the CAM 
concentration enabling calibration in a linear model (Figure S1).  
The sensitivity of the CAM distribution to the path is reflected in Figure 1b, which 
represents the weight ratio of adsorbed and encapsulated antibiotic with respect to the 
dry weight of mineral. The amount of CAM loaded through the Ca-path was greater 
than through the Pho-path for both cHAp and ACP. This difference mainly arises from 
the encapsulated antibiotic since the concentration of adsorbed CAM is similar for both 
ACP and cHAp NPs. This feature is consistent with the similar surface areas found for 
both kind of NPs.
24
 Accordingly, hereafter discussion of the results have been mainly 
focused on CAM(Ca)-loaded cHAp and ACP NPs.  
Control NPs, denoted CAM(c)/cHAp and CAM(c)/ACP, were prepared using an ex 
situ loading approach: deposition of 500 L of 150 mM CAM solution onto 50 mg of 
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already synthetized cHAp and ACP NPs, respectively. The distribution of the 
accumulated antibiotic was completely different from those found for in situ loaded NPs 
(Figure S2): the amount of CAM that penetrated into the mineral matrix for 
encapsulation was significantly smaller than the antibiotic adsorbed on the surface.  
Figure 2a compares the FTIR spectra recorded for CAM alone, unloaded cHAp NPs, 
CAM(Ca)/cHAp NPs as prepared (i.e. with both adsorbed and encapsulated CAM), and 
CAM(Ca)/cHAp NPs after eliminate the antibiotic adsorbed onto the surface washing 
with PBS-EtOH (i.e. with encapsulated CAM only). The characteristic bands of cHAp 
(at around 1021 cm
-1
)
24
 and of CAM (3350-1300 cm
-1
 interval)
37
 appear in the spectra 
recorded for CAM(Ca)/cHAp NPs as prepared and washed with PBS-EtOH. Thus, 
presence of CAM is proved by the absorption peaks at 3332 (O–H stret), 3248 (N–H 
stret), 3080 (C–H stret), 1683 / 1563 (amide I / amide II of the 2,2-dichlor-acetamide 
moiety), and 1515 / 1342 cm
-1
 (nitro / nitro-phenyl group). The absorption peaks of 
CAM in loaded ACP samples were detected at very similar positions (Figure S3).  
Results from the characterization of unloaded and CAM(Ca)-loaded mineral NPs by 
XRD are summarized in Figure 2b and Table 1. The reflections identified for CAM 
alone (Figure S4) are fully consistent with those reported in the literature for the crystal 
structure of most stable antibiotic form (alicyclic CAM).
38,39
 The most intense 
reflections, which correspond to the (401) and (114) planes with d-spacing 0.428 nm, 
together with the (002) (d= 1.108 nm), (201) (d= 0.815 nm), (202) (d= 0.687 nm) and 
(203) (d= 0.564 nm), allow identification of the antibiotic in the loaded NPs, since the 
rest of the peaks overlap with characteristic reflections of cHAp and ACP.  
Both the crystallinity and the crystallite size are lower for CAM-loaded ACP and, 
especially, cHAp samples than for the unloaded ones (Table 1). This observation 
reflects that the antibiotic affects the formation of crystallization nuclei, reducing both 
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their number and size. This phenomenon has been attributed to the competition between 
CAM···mineral interactions and CAM intramolecular hydrogen bonds, the latter being 
characteristic of the alicyclic form of the antibiotic (see next sub-section). The 
difficulties in the formation of CAM···mineral interactions and the stability of the 
alicyclic CAM preclude the role of the antibiotic as nucleating agent. Furthermore, the 
incorporation of the antibiotic to the mineral matrix causes steric hindrance, inhibiting 
the growth of already formed crystallization nuclei.  
SEM and TEM micrographs of CAM alone and CAM(Ca)-loaded mineral NPs, after 
elimination of the antibiotic at the surface with PBS-EtOH, are displayed in Figure 3. 
CAM is a crystalline antibiotic that organizes in nanoplates (Figure 3a). The 
nanospherical and nanorod-like morphologies of CAM(Ca)/ACP (Figure 3b) and 
CAM(Ca)/cHAp (Figure 3c), respectively, are similar to those of unloaded minerals,
22
 
evidencing that the encapsulation of the antibiotic does not modify the morphology of 
the NPs. Accordingly, the loading strategy promotes the homogeneous integration of the 
antibiotic into the mineral matrix during the biomineralization process.  
In previous work we described the ability of both ACP and cHAp to adsorb 
biophosphates (e.g. pyrophosphates and triphosphates, abbreviated 
4
72OP  and polyP, 
respectively) and biophosphonates (e.g. amino-tris(methylenephosphonic acid), 
abbreviated ATMP),
24
 which are important for bone regeneration. Such bioadsorption 
capacity has been used in this study to protect the loaded antibiotic during the delivery 
process.  
Figure 4 displays SEM micrographs of CAM(Ca)/ACP and CAM(Ca)/cHAp samples 
after incubation with 
4
72OP , polyP or ATMP solutions, as described in the Supporting 
Information. Comparison with micrographs displayed in Figure 3 reflects the formation 
of superficial protecting layers. The significant morphological changes have been 
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attributed to the fact that, after the first stages of the bioadsorption process, a surface-
induced crystal growing process occurred for the three biocoatings. On the other hand, 
quantification of the adsorbed and encapsulated amount of CAM indicates that the 
biocoating does not interfere with the loaded antibiotic and, therefore, does not induce 
its premature release during the bioadsorption process (Figure S5). FTIR and X-ray 
diffraction studies (Figures S6-S10, and Table S1) confirmed the presence of the 
biocoating and its negligible influence in the internal structure of CAM-loaded mineral 
samples. 
 
Effect of the loading in the bioactivity of CAM 
The alicyclic form of CAM has been associated to its antimicrobial action.
40
 In this 
bioactive conformation the hydroxyl groups of the antibiotic are engaged in closing an 
alicyclic ring by hydrogen bonding (Scheme 2). Accordingly, the activity of CAM 
could be altered by structural changes that affect the functional character of such 
hydroxyl groups. In this sub-section, we examine the effect of CAM···mineral 
interactions in the bioactive response of the antibiotic.  
 
Scheme 2 
 
As mentioned above, the peaks identified in the diffractograms recorded for 
CAM(Ca)/cHAp and CAM(Ca)/ACP NPs before (Figure 2a) and after applying 
biocoatings (Figures S9 and S10) correspond to those identified for the crystal structure 
of CAM (Figure S4). Accordingly, the crystalline structure of the antibiotic remains 
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unaltered during both the loading and coating processes. In addition, the position of the 
O–H absorption band in the FTIR spectra is the same for the antibiotic alone and loaded 
(Figures 2a, S3 and S6-S8). Thus, the alicyclic ring is apparently unaltered by the 
formation of CAM···mineral, CAM···biocoating and mineral···biocoating interactions, 
which suggests that the antibiotic is not forming specific hydrogen bonding interactions 
with the mineral and/or the biocoating.  
In order to confirm that the bioactive conformation of CAM was not altered by the 
loading and bioadsorption processes, the activity of the loaded antibiotic loaded was 
tested against representative Gram-negative bacteria (E. coli) and compared with that of 
free antibiotic. Figure 5a plots the relative growth rate of the partially inhibited cultures 
against the logarithm of the antibiotic concentration for free CAM, CAM(Ca)/cHAp and 
CAM(Ca)/ACP. Symmetrical sigmoid curves similar to the dose-response curves of 
many biological systems were obtained in all cases. The central portion of the curve 
approaches linearity, allowing a graphic extrapolation of the 50% growth inhibition 
levels. The half maximal inhibitory concentration (IC50) of antibiotic determined for 
free CAM, CAM(Ca)/cHAp and CAM(Ca)/ACP is 0.96, 0.94 and 0.94 g/mL, 
respectively, reflecting that the bioactivity of CAM is preserved in loaded mineral NPs. 
Figure 5b and 5c compares the bacterial growth inhibition of uncoated and biocoated 
CAM(Ca)/cHAp and CAM(Ca)/ACP NPs, respectively. It is worth noting that the 
bioadsorption of polyP, 
4
72OP  and ATMP does not alter the inhibitory characteristics of 
the antibiotic, evidencing that CAM preserves the bioactive conformation.  
 
CAM-Release in PBS and cell culture media 
Quantitative release assays in the simplest physiological medium, PBS, were 
performed with CAM(Ca)/cHAp and CAM(Ca)/ACP NPs, CAM(c)/cHAp and 
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CAM(c)/ACP NPs being used as controls. Results displayed in Figure 6a indicate that, 
although the amount of loaded antibiotic was entirely released after 72 h in all cases, 
the release rate was slower for CAM(Ca)/cHAp than for CAM(Ca)/ACP. More 
specifically, the time necessary to release 50% of loaded CAM (t50) was 23 and 7 h 
respectively. On the other hand, the release rate was significantly faster for control NPs 
than for minerals loaded using the in situ approach (i.e. t50 12 and 4 h for 
CAM(c)/cHAp and CAM(c)/ACP, respectively), evidencing that the encapsulation 
achieved by the latter procedure exerts a regulating effect. The sustained antibiotic 
release observed for the in situ loaded NPs has been attributed to the slow diffusion of 
the encapsulated CAM through the mineral matrix.  
The behavior of CAM(Ca)-loaded mineral NPs coated with polyP, 
4
72OP  and ATMP 
(Figures 6b-d) was similar to that described for the uncoated systems. The antibiotic 
release rate was faster for ACP than for cHAp, independently of the coating. 
Furthermore, the release rate was faster for control NPs than for those loaded using the 
in situ approach. Quantitative comparison between uncoated and coated 
CAM(Ca)/cHAp reflects that the release rate is the same for uncoated and polyP-coated 
NPs (e.g. t50 23 h in both cases), whereas 
4
72OP  and, specially, ATMP biocoatings 
tend to accelerate the delivery process (e.g. t50 20 and 17 h, respectively).  
Antibiotic release assays from uncoated and coated CAM(Ca)/cHAp and 
CAM(Ca)/ACP NPs were also carried out in cell culture media using three different cell 
lines: human umbilical vein endothelial cells (HUVEC), green monkey kidney 
fibroblast cells (COS-1), and human breast cancer cells (MCF-7). The release profiles, 
which are displayed in Figures 7 and S11, were very similar to those obtained in PBS. 
Thus, the retardation effect increased with the crystallinity of the sample, the release 
from cHAp NPs being slower than from ACP NPs. These characteristic trends were also 
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identified for biocoated NPs, the influence of the chemical specie adsorbed at the 
surface of the mineral NPs being practically negligible. However, the most important 
result is that the antibiotic release profiles obtained for uncoated and biocoated 
CAM(Ca)/cHAp and CAM(Ca)/ACP NPs are totally independent of cell line. 
The sustained release of CAM displayed in vitro by both cHAp and ACP, which is 
not affected by the biological environment, suggests that such mineral NPs could act as 
antitumoral nanoplatforms for in vivo treatments. More specifically, our results clearly 
indicate that cHAp and ACP NPs act as efficient vehicles for the CAM transport and 
delivery. 
 
Can CAM-loaded mineral NPs be used to fight cancer cells? 
In previous sub-sections, we proved that cHAp and ACP NPs prepared using the in 
situ Ca-path are efficient platforms for the loading of bioactive CAM and its delayed 
release with respect to platforms prepared using the usual ex situ incubation approach. 
In this section, we examine the response of cells to CAM(Ca)/cHAp and 
CAM(Ca)/ACP NPs. Initially, an exploratory study was conducted using the 
electroporation technique to facilitate the permeation of CAM-loaded mineral NPs 
across cell membranes, since the anticancer therapy using antibiotics is based on the 
targeting of mitochondria.
15-18
 Electroporation is the increment of the cell membrane 
permeability by exposing the cells to short electric current pulses from an external 
source. Such increase in permeability, which is related with the formation of nanoscale 
defects or pores in the cell membrane, allows the direct physical transfer of numerous 
kinds of chemical species into cells. In our case, we use this effect to ensure the entry of 
the NPs into the cells. 
13 
 
Unloaded and CAM-loaded mineral NPs, without and with biocoating, were 
introduced in culture media with non-cancerous (HUVEC and COS-1) and cancerous 
(MCF-7) cells, which were electroporated to facilitate the internalization process. A 
sub-lethal dose of CAM was used in these assays in order to avoid generalized 
cytotoxicity (i.e. a dose that will kill less than 5% of the test cells) and allow the 
population of unaffected cells to recover over time. Then, they were seeded in the 
culture plate and evaluated at different times. In order to investigate the effects of the 
antibiotic in living cells, the viability was determined through the MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. The cytotoxic response 
of HUVEC, COS-1 and MCF-7 cell lines exposed to the increasing concentrations of 
CAM is displayed in Figure 8.  
As it was expected due to the use of sub-lethal doses, electroporated cells remained 
practically unaffected after the internalization of unloaded cHAp and ACP NPs (Figures 
S12 and S13, respectively), independently of both the cell type and the biocoating. Plots 
representing the variation of survival cells with time indicate an immediate reduction of 
the viability. This effect, which is frequently observed after the incorporation of agents 
extraneous to the culture medium, has been associated to the high concentration of 
mineral NPs and, therefore, to the high content of Ca
2+
 inside the electroporated cells. 
After this initial effect, cells recover in number over time until reach 100% of the 
initial viability after 120 h. 
Addition of uncoated and biocoated CAM(Ca)/HAp NPs into non-cancerous cell 
models, HUVEC and COS-1 (Figures 9a and 9b, respectively), caused an almost 
identical response. Thus, the fraction of surviving non-cancerous cells after 120 h was 
100%, evidencing that CAM is not inhibiting mitochondrial functions and, therefore, 
preserving the cell viability. In contrast, CAM(Ca)/HAp NPs damaged MCF-7 
14 
 
cancerous cells (Figure 9c), causing a high percentage of cells to die (39%5%). The 
different response of normal and cancer cells against CAM(Ca)-loaded mineral NPs is 
due to a combination of two factors: (i) mitochondria are more abundant in cancerous 
cells than in non-cancerous cells;
17
 and (ii) the similarity between bacterial and 
mitochondrial ribosomes.
15
 
As CAM(Ca)-loaded cHAp NPs are very toxic for cancer cells as compared to 
innocuous unloaded cHAp, protection of the antibiotic using biocoatings is expected to 
enhance such destructive effects. Effectively, the percentage of surviving cells drops 
drastically for CAM(Ca)/cHAp NPs coated with polyP, 
4
72OP  and ATMP (Figure 9c). 
More specifically, after 120 h the percentage of dead cells increased from 39%5% for 
uncoated NPs to 59%3% (polyP), 51%5% (
4
72OP ) and 51%4% (ATMP) for coated 
NPs. These results indicate that the protecting role exerted by the biocoating, especially 
by polyP, enhances the efficiency of the antibiotic as anticancer agent. According to 
previous discussion (Figure 8), this phenomenon cannot be attributed to a delay in the 
release of the antibiotic (i.e. release curves for uncoated and biocoated CAM(Ca)-
loaded NPs were very similar). Instead, two different hypotheses can be considered two 
explain the protection offered by the biocoating: (1) CAM···biocoating complexes 
allow to protect the antibiotic molecules against enzymatic degradation, avoiding the 
premature reduction in the amount of effective CAM as anticancer agent. More 
specifically, acetyltransferases covalently modify CAM resulting in structural 
alterations (i.e. O-acetylation through deprotonation of the hydroxyl group) that impair 
target binding;
41
 and (2) the dissolved biocoating molecules capture the antibiotic ones, 
transporting them to the mitochondria to enhance the antitumor activity (i.e. they act as 
targeted carriers).  
15 
 
In order to ascertain if the protecting role attributed to the biocoating affects to the 
CAM adsorbed onto mineral NPs only or extends to the antibiotic encapsulated into the 
cHAp matrix, additional assays were performed by introducing uncoated and biocoated 
CAM(c)/HAp NPs into electroporated HUVEC, COS-1 and MCF-7 cells. The 
population of surviving HUVEC and COS-1 cells after 120 h was 100% (Figure S14) 
while the amount of MCF-7 cells decreased (Figure 9d). However, such reduction was 
not only smaller than that observed for CAM(Ca)/cHAp but also independent of the 
presence of biocoating. Thus, the percentage of dead MCF-7 cells after 120 h is 
34%4% for uncoated CAM(c)/cHAp, remaining at 35%5% , 32%3% and 32%5% 
for NPs coated with polyP, 
4
72OP  and ATMP, respectively. Comparison of results 
displayed in Figures 9c and 9d indicates that CAM molecules biomineralized inside the 
cHAp matrix through the in situ polymerization approach play a crucial role in the 
success of biocoated CAM(Ca)/cHAp NPs as antitumoral platforms. Thus, the 
biocoating layer probably prevents from degradation before the internalization of the 
NPs, increasing the therapeutic efficacy of CAM.  
Qualitative analysis of the results obtained for CAM(Ca)/ACP (Figure S15a-c) and 
CAM(c)/ACP (Figures S15d and S16) reflected a similar behavior. After 120 h, 100% 
of non-cancerous cells survived, while the percentage of dead MCF-7 cells grew from 
22%3% for uncoated CAM(Ca)/ACP to 44%4% (polyP), 33%4% (
4
72OP ) or 
33%2% (ATMP) for coated NPs. From a quantitative point of view, the antitumor 
efficacy of the loaded antibiotic is around 15-20% higher for cHAp than for ACP, 
independently of the biocoating. This feature has been attributed to the fact that the 
release from CAM(Ca)/cHAp is slower than from CAM(Ca)/ACP.   
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Proving the antitumor efficacy of CAM-loaded mineral nanoparticles via endocytic 
pathway 
The last aspect to be addressed in this work refers to the cellular uptake of biocoated 
CAM(Ca)/cHAp NPs from the surrounding fluid without artificially created transient 
pores at the cell membrane (i.e. without apply electroporation). Endocytosis is the form 
of active transport used by almost all living eukaryotic cells to internalize extracellular 
materials that cannot pass through the membrane by simple diffusion. It is known that 
HAp enters into cells through the endocytic pathway.
42-44
 As the endocytosis activity of 
cancer cells is greater than that of normal cells,
45-47
 in this section we focus on the effect 
of both the biocoating and the loaded antibiotic in the efficiency of the endocytic 
process, which is expected to be closely related with the antitumor efficacy of the 
proposed therapeutic platforms. 
The effect of the incorporation of unloaded cHAp particles into the cell culture was 
practically nil (Figure S17), the amount of surviving HUVEC, COS-1 and MCF-7 cells 
after 120 h being around 100%, independently of the biocoating. In contrast, the 
incorporation of biocoated cHAp NPs loaded with a sub-lethal dose of CAM (Figure 
10) inhibits selectively the viability of MCF-7 cancerous cells, while the response of 
HUVEC and COS-1 noncancerous cells is the same that for unloaded cHAp (i.e. 100% 
of surviving cells after 120 h). The inhibitory effects of CAM(Ca)/cHAp are severely 
affected by both presence and chemical nature of the biocoating, such dependence being 
considerably more pronounced than that observed in the previous sub-section for 
permeable electroporated cells. Thus, although for uncoated CAM(Ca)/cHAp the 
percentage of dead MCF-7 cells was 265% after 48 h, 98% of the cell viability was 
recovered after 120 h (Figure 10c). Comparison of the surviving cells profiles obtained 
by contacting uncoated CAM(Ca)/cHAp with electroporated and non-electroporated 
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MCF-7 cells (Figures 9c and 10c, respectively) indicates that, in the latter case, the 
antibiotic release occurs mostly prior to the internalization of the NP. The apparition of 
temporary pores in cell membranes during the application of the electric field favors the 
rapid uptake of the CAM(Ca)/cHAp particles, ensuring the effectivity of the antibiotic 
released inside the cells once the cell membrane reseals after electroporation. In 
contrast, the anticancer efficacy of the antibiotic loaded in uncoated NPs is drastically 
limited by the rate of the endocytic process in absence of electroporation. 
In opposition, biocoated CAM(Ca)/cHAp NPs improves the antitumor effectivity in 
absence of electroporation (Figure 10c). More specifically, the percentage of dead 
cancerous cells after 120 h is 585%, 505% and 465% for NPs coated with polyP, 
4
72OP  and ATMP, respectively. Accordingly, the barrier effect exerted by the 
biocoating with respect to the antibiotic release eliminates the rate of the endocytic as 
limiting step of its antitumor efficacy. The effectivity of such blocking effect varies as 
follows: polyP > 
4
72OP  > ATMP, indicating that CAM(Ca)/cHAp coated with polyP is 
the most effective antitumor platform.  
In order to corroborate the performance of biocoated CAM(Ca)/cHAp NPs as smart 
antitumor platforms, additional experiments were conducted using MIA PaCa-2 
pancreas cancer cells. Results, which are displayed in Figure 10d, show that the 
percentage of dead cancerous cells after 120 h is 546%, 465% and 415% for 
CAM(Ca)/cHAp NPs coated with polyP, 
4
72OP  and ATMP, respectively. These values 
are fully consistent with those obtained using MCF-7 cells (Figure 10c), confirming not 
only the barrier effect exerted by the biocoating but also the antitumor efficacy of 
antibiotic when it is appropriately released. 
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CONCLUSIONS 
In the present study, we prove the very high antitumor activity of the following 
system: CAM loaded into cHAp NPs and, subsequently, coated with polyP. The 
efficiency and selectivity of CAM(Ca)/cHAp NPs coated with polyP have been 
demonstrated by the reduction of cancerous cells and the surviving of normal cells. The 
preparation strategy is essential to maximize the anticancer properties of that 
nanoplatform. Firstly, the in situ synthesis allows not only adsorbing antibiotic onto the 
NPs but also encapsulating CAM into the mineral matrix. Secondly, the amount of 
encapsulated antibiotic is higher for the Ca-path than for the Pho-path. Thirdly, 
hydrothermal conditions to produce cHAp are preferred with respect to aging conditions 
to obtain ACP. This is because the antibiotic release from cHAp is slower than from 
ACP, allowing a greater control of the antitumor activity. Although the biocoating is not 
affecting the antibiotic release process, its presence causes a drastic reduction in the 
amount of surviving cancer cells. Several hypotheses have been proposed to explain the 
role of polyP (e.g. as antibiotic carrier to target mitochondria or as antibiotic protector 
against degradation), even though more work is necessary is to provide complete 
understanding of the experimental observations related with the biocoating. In 
summary, CAM(Ca)/cHAp NPs coated with polyP in are promising bioplatforms for 
cancer therapy.  
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Table 1. Crystallinity (c) and crystallite size (L) of the unloaded and CHL-loaded 
mineral samples. 
 c L (nm) 
cHAp 0.660.03 572 
CAM(Ca)/HAp 0.200.02 362 
ACP 0.100.02 71 
CAM(Ca)/ACP 0.060.01 61 
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CAPTIONS TO FIGURES 
Figure 1. (a) Scheme to illustrate the four in situ synthetic strategies used to prepare 
CAM-loaded mineral NPs: CAM(Pho)/cHAp, CAM(Pho)/ACP, CAM(Ca)/cHAP and 
CAM(Ca)/ACP. (b) Distribution of the antibiotic loaded in situ during the synthesis of 
cHAp and ACP NPs using the Pho- and Ca-paths. The amount of antibiotic adsorbed 
onto the surface and encapsulated into the matrix has been evaluated separately (see 
text). The total amount of loaded CAM corresponds to the sum of adsorbed and 
encapsulated. The loading ratio is expressed with respect to the weight of dry mineral. 
Figure 2. (a) Selected regions of the FTIR spectra of CAM, cHAp, CAM(Ca)/cHAp 
as prepared (with both adsorbed and encapsulated CAM), and CAM(Ca)/cHAp after 
washing with PBS-EtOH (with encapsulated CAM only). (b) X-ray diffraction patterns 
of unloaded and CAM(Ca)-loaded cHAp and ACP samples as prepared. 
Figure 3. SEM (left) and TEM (right) images of (a) CAM crystals, (b) 
CAM(Ca)/ACP and (c) CAM(Ca)/cHAp NPs after washing with PBS-EtOH (loaded 
with encapsulated CA only).   
Figure 4. SEM images of CAM(Ca)-loaded ACP (left) and cHAp (right) NPs after 
incubation with (a) polyP, (b) 
4
72OP  and (c) ATMP aqueous solutions. The arrows 
indicate the presence of crystals of the bioadsorbed compounds. 
Figure 5. Inhibition of E. coli growth by CAM. Results are expressed as a 
percentage of the control against the logarithm concentration of antibiotic for: (a) free 
CAM, CAM(Ca)/cHAp and CAM(Ca)/ACP; (b) uncoated and biocoated 
CAM(Ca)/cHAp NPs; and (c) uncoated and biocoated CAM(Ca)/ACP NPs. 
Figure 6. Antibiotic release profiles in PBS for (a) uncoated, (b) polyP coated, (c) 
4
72OP  coated and (d) ATMP coated CAM(Ca)-loaded cHAp and ACP NPs. CAM-
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incubated samples (uncoated and biocoated CAM(c)/cHAp and CAM(c)/ACP NPs) 
were used as control NPs.   
Figure 7. Antibiotic release profiles in different cell culture media (HUVEC, COS-1 
and MCF-7 cell lines) for (a) uncoated CAM(Ca)/cHAp, (b) uncoated CAM(Ca)/ACP, 
(c) CAM(Ca)/cHAp coated with polyP, and (d) CAM(Ca)/ACP coated with polyP. 
CAM-incubated samples, CAM(c)/cHAp and CAM(c)/ACP, were used as control. 
Results obtained for NPs coated with 
4
72OP  and ATMP are displayed in Figure S11. 
Figure 8. Cytotoxicity curves of CAM. Cell viability of HUVEC, COS-1 and MCF-7 
cells with increasing concentration of CAM (in µM) evaluated at (a) 24 h and (b) 48 h 
of culture. Curves are expressed as percentage of surviving cells relative to the control 
against the logarithm of CAM concentration. 
Figure 9. Temporal variation of the percentage of surviving cells after the 
incorporation of uncoated and biocoated CAM(Ca)/cHAp NPs to electroporated (a) 
HUVEC, (b) COS-1 and (c) MCF-7 cells, and (d) CAM(c)/cHAp NPs to electroporated 
MCF-7 cells.  
Figure 10. Temporal variation of the percentage of surviving cells after the 
incorporation of uncoated and biocoated CAM(Ca)/cHAp NPs to non-electroporated (a) 
HUVEC, (b) COS-1, (c) MCF-7 and (d) MIA PaCa-2 cells.  
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